Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Trial Details

NCT ID

NCT07555938

Phase

PHASE3

Sponsor

Hoffmann-La Roche

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Cevostamab
Pomalidomide
Dexamethasone
Daratumumab
Elotuzumab
Carfilzomib

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Irvine, California, United States|33.66946,-117.82311
New Haven, Connecticut, United States|41.30815,-72.92816
Washington D.C., District of Columbia, United States|38.89511,-77.03637
Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treat…
Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →